Kastar 3-Pack BN-V428 Battery and LTD2 f USB 1 year warranty Replacement Charger $32 Kastar 3-Pack BN-V428 Battery and LTD2 USB Charger Replacement f Electronics Camera Photo Kastar 3-Pack BN-V428 Battery and LTD2 f USB 1 year warranty Replacement Charger BN-V428,Electronics , Camera Photo,Kastar,Replacement,and,/femoral1417144.html,srs-advertisement.com,$32,LTD2,f,Charger,Battery,3-Pack,USB $32 Kastar 3-Pack BN-V428 Battery and LTD2 USB Charger Replacement f Electronics Camera Photo BN-V428,Electronics , Camera Photo,Kastar,Replacement,and,/femoral1417144.html,srs-advertisement.com,$32,LTD2,f,Charger,Battery,3-Pack,USB
BN-V408 V408U V408US
BN-V416 V416U V416US
BN-V428 V428U V428US
BN-V438 V438U V438US
BN-V856 V856U V856US
GR-D20 GR-D200 D201 GR-D2000 GR-D21 GR-D22 GR-D23
GR-D30 D30US GR-D31 D31US GR-D32 D32US GR-D33 D33US GR-D34 D34US
GR-D40 GR-D43 GR-D47
GR-D50 GR-D51 GR-D53 GR-D54
GR-D60 GR-D61 GR-D63 GR-D65
GR-D70 D70US GR-D71 D71US GR-D72 D72US GR-D73 D73US GR-D74 D74US
GR-D90 D90U D90US GR-D91 D91US GR-D92 GR-D93 D93US GR-D94 D94US GR-D95US
GR-D230 GR-D200US GR-D220 GR-D225 GR-D228 GR-D230 D230US GR-D231 GR-D238 GR-D500
GR-DV300 GV-DV301 GR-DV400 GR-DV500 GR-DV550 GR-DV600 GR-DV700 GR-DV800 DV800US GR-DV801 GR-DV900 GR-DV1800 GR-DV2000 DV2000U GR-DV3000 DV3000U GR-DV3500 GR-DV4000 DV4000US GR-DV5000 DV5000US
GR-DVA10 GR-DVA11 GR-DVA20 GR-DVA22 GR-DVA23 GR-DVA30 GR-DVA33 GR-DVA101
GR-DVF10 GR-DVF20 GR-DVF202 GR-DVF303 GR-DVF305 GR-DVF505
GR-DVL100 DVL100U GR-DVL105 DVL105U GR-DVL107 DVL107U GR-DVL108 GR-DVL109 GR-DVL120 GR-DVL140 GR-DVL145 GR-DVL150 GR-DVL155 GR-DVL157 GR-DVL160 GR-DVL166 GR-DVL167
GR-DVL200 DVL200U GR-DVL205 GR-DVL207 GR-DVL210 DVL210U GR-DVL220 DVL220U GR-DVL257
GR-DVL300 DVL300U GR-DVL305 GR-DVL307 GR-DVL308 GR-DVL309 GR-DVL310 GR-DVL313 GR-DVL315 GR-DVL317 GR-DVL320 GR-DVL322 GR-DVL323 GR-DVL326 GR-DVL355 GR-DVL357 GR-DVL365 GR-DVL367
GR-DVL400 GR-DVL410 GR-DVL420 GR-DVL450
GR-DVL500 GR-DVL505 GR-DVL507 GR-DVL510 GR-DVL512 GR-DVL515 GR-DVL517 GR-DVL520 GR-DVL522 GR-DVL525 GR-DVL555 GR-DVL557 GR-DVL567
GR-DVL600 GR-DVL607 GR-DVL610
GR-DVL700 GR-DVL707 GR-DVL710 GR-DVL715 GR-DVL720 GR-DVL722 GR-DVL725 GR-DVL728 GR-DVL765 GR-DVL767
GR-DVL800 GR-DVL805 GR-DVL810 GR-DVL815 GR-DVL817 GR-DVL820 GR-DVL822 GR-DVL828 GR-DVL865 GR-DVL867
GR-DVL900 GR-DVL910 GR-DVL915 GR-DVL920 GR-DVL925 GR-DVL970
GR-DZ7 DZ7US GR-HD1 HD1US GR-PD1 GR-VF1 GR-Z7
GY-HD100 HD101 HD110 HD111
JY-HD10 HD10U JY-VS200 VS200U
Vermeer et al. report that gain-of-function mutations in the ubiquitin ligase component Kelch-like 24 (KLHL24), which occur in a subset of patients with epidermolysis bullosa simplex, promote dilated cardiomyopathy via excessive degradation of desmin. The cover image is a pseudocolored electron micrograph showing the ultrastructure of dynamically loaded, human induced pluripotent stem cell–derived engineered heart tissues.
S Indicates subscriber content
Persons living with HIV (PLWH) are at increased risk of tuberculosis (TB). HIV-associated TB is often the result of recent infection with Mycobacterium tuberculosis (Mtb) followed by rapid progression to disease. Alveolar macrophages (AM) are the first cells of the innate immune system that engage Mtb, but how HIV and antiretroviral therapy (ART) impact on the anti-mycobacterial response of AM is not known. To investigate the impact of HIV and ART on the transcriptomic and epigenetic response of AM to Mtb, we obtained AM by bronchoalveolar lavage from 20 PLWH receiving ART, 16 control subjects who were HIV-free (HC), and 14 subjects who received ART as pre-exposure prophylaxis (PrEP) to prevent HIV infection. Following in-vitro challenge with Mtb, AM from each group displayed overlapping but distinct profiles of significantly up- and down-regulated genes in response to Mtb. Comparatively, AM isolated from both PLWH and PrEP subjects presented a substantially weaker transcriptional response. In addition, AM from HC subjects challenged with Mtb responded with pronounced chromatin accessibility changes while AM obtained from PLWH and PrEP subjects displayed no significant changes in their chromatin state. Collectively, these results revealed a stronger adverse effect of ART than HIV on the epigenetic landscape and transcriptional responsiveness of AM.
Wilian Correa-Macedo, Vinicius M. Fava, Marianna Orlova, Pauline Cassart, Ron Olivenstein, Joaquín Sanz, Yong Zhong Xu, Anne Dumaine, Renata H.M. Sindeaux, Vania Yotova, Alain Pacis, Josée Girouard, Barbara Kalsdorf, Christoph Lange, Jean-Pierre Routy, Luis B. Barreiro, Erwin Schurr
BACKGROUND. Primary polydipsia, characterized by excessive fluid intake, carries the risk of water intoxication and hyponatremia, but treatment options are scarce. Glucagon-like peptide-1 (GLP-1) reduces appetite and food intake. In experimental models, they also play a role in thirst and drinking behavior. The aim of this trial was to investigate whether GLP-1 receptor agonists reduce fluid intake in patients with primary polydipsia. METHODS. In this randomized, double-blind, placebo-controlled, 3-week crossover-trial, 34 patients with primary polydipsia received weekly dulaglutide (Trulicity®) 1.5mg and placebo (0.9% sodium chloride). During the last treatment week, patients attended an 8-hour evaluation visit with free water access. The primary endpoint was total fluid intake during the evaluation visits. Treatment effects were estimated using linear mixed-effects models. In a subset of 15 patients and additional 15 matched controls, thirst perception and neuronal activity in response to beverage pictures were assessed by functional MRI. FINDINGS. Patients on dulaglutide reduced fluid intake by 490ml [95%-CI -780, -199], p=0.002, from 2950ml [95% CI 2435, 3465] on placebo to 2460ml [95% CI 1946, 2475] on dulaglutide (model estimates), corresponding to a relative reduction of 17%. 24-hour urinary output was reduced by -943ml [95%-CI -1473, -413], p=0.001. Thirst perception in response to beverage pictures was higher in patients with primary polydipsia versus controls and lower on dulaglutide versus placebo, but functional activity was similar between groups and treatments. INTERPRETATION. GLP-1 receptor agonists reduce fluid intake and thirst perception in patients with primary polydipsia and could therefore be a treatment option for these patients.
Bettina Winzeler, Clara Odilia Sailer, David Coynel, Davide Zanchi, Deborah R. Vogt, Sandrine Andrea Urwyler, Julie Refardt, Mirjam Christ-Crain
BACKGROUND. Passive immunotherapy with convalescent plasma (CP) is a potential treatment for COVID-19 for which evidence from controlled clinical trials is inconclusive. METHODS. We conducted a randomized, open-label, controlled clinical trial at 27 hospitals in Spain. Patients had to be admitted for COVID-19 pneumonia within 7 days from symptom onset and not on mechanical ventilation or high flow oxygen devices. Patients were randomized 1:1 to treatment with CP in addition to standard of care (SOC) or to the control arm receiving only SOC. The primary endpoint was the proportion of patients in categories 5 (non-invasive ventilation or high-flow oxygen), 6 (invasive mechanical ventilation or extracorporeal membrane oxygenation [ECMO]), or 7(death) at 14 days, and primary analysis was performed in the intention-to-treat population. RESULTS. Between April 4, 2020 and February 5, 2021, 350 patients were randomly assigned to either CP (n=179) or SOC (n=171). At 14 days, proportion of patients on categories 5, 6 or 7 was 11.7% in CP group versus 16.4% in control group (p=0.205). The difference was greater at 28 days, with 8.4% of patients in categories 5-7 in CP group versus 17.0% in control group (p=0.021). The difference in overall survival did not reach statistical significance (HR 0.46, 95%CI 0.19-1.14, log-rank p=0.087). CONCLUSION. CP showed a significant benefit in preventing progression to non-invasive ventilation or high-flow oxygen, invasive mechanical ventilation or ECMO, or death at 28 days. The effect on the predefined primary endpoint at 14 days and the effect on overall survival were not statistically significant. TRIAL REGISTRATION. clinicaltrials.gov, NCT04345523 FUNDING. Government of Spain, Instituto de Salud Carlos III.
Cristina Avendaño-Solá, Antonio Ramos-Martínez, Elena Muñez-Rubio, Belen Ruiz-Antorán, Rosa Malo de Molina, Ferran Torres, Ana Fernández-Cruz, Jorge Calderon-Parra, Concepcion Payares-Herrera, Alberto Díaz de Santiago, Irene Romera Martínez, Ilduara Pintos, Jaime Lora-Tamayo, Mikel Mancheño-Losa, Maria Liz Paciello Coronel, AL Martinez-Gonzalez, Julia Vidán-Estévez, Maria José Nuñez-Orantos, Maria Isabel Saez-Serrano, Maria Lourdes Porras-Leal, Maria del Castillo Jarilla-Fernández, Paula Villares, Jaime Perez de Oteyza, Ascensión Ramos-Garrido, Lydia Blanco, Maria Elena Madrigal-Sánchez, Martín Rubio-Batllés, Ana Velasco-Iglesias, José Ramón Paño-Pardo, JA Moreno-Chulilla, Eduardo Muñiz-Diaz, Inmaculada Casas-Flecha, Mayte Pérez-Olmeda, Javier García-Pérez, Jose Alcami, José Luis Bueno, Rafael F. Duarte
Atrial natriuretic peptide (ANP) is an important hormone in cardiovascular biology. It is activated by the protease corin. In pregnancy, ANP and corin promote uterine spiral artery remodeling, but the underlying mechanism remains unknown. Here we report an ANP function in uterine decidualization and TNF-related apoptosis-induced ligand (TRAIL)-dependent death in spiral arterial smooth muscle cells (SMCs) and endothelial cells (ECs). In ANP- or corin-deficient mice, uterine decidualization markers and TRAIL expression were decreased, whereas in cultured human endometrial stromal cells (HESCs), ANP increased decidualization and TRAIL expression. In uterine spiral arteries from pregnant wild-type mice, SMC and EC loss occurred sequentially before trophoblast invasion. In culture, TRAIL from decidualized HESCs induced apoptosis in uterine SMCs, but not in ECs with low TRAIL receptor expression. Subsequently, cyclophilin B was identified from apoptotic SMCs that up-regulated endothelial TRAIL receptor and caused apoptosis in ECs. These results indicate that ANP promotes decidualization and TRAIL expression in endometrial stromal cells, contributing to sequential events in remodeling spiral arteries, including SMC death and cyclophilin B release, which in turn induces TRAIL receptor expression and apoptosis in ECs.
Wei Zhang, Shuo Li, Jinglei Lou, Hui Li, Meng Liu, Ningzheng Dong, Qingyu Wu
Little is known about how cells regulate and integrate distinct biosynthetic pathways governing differentiation and cell division. For B-lineage cells it is widely accepted that activated cells must complete several rounds of mitosis before yielding antibody-secreting plasma cells. However, we report that marginal zone (MZ) B cells, innate-like naïve B cells known to generate plasma cells rapidly in response to blood-borne bacteria, generate functional plasma cells despite cell cycle arrest. Further, short-term Notch2 blockade in vivo reversed division-independent differentiation potential and decreased transcript abundance for numerous mTORC1- and Myc-regulated genes. Myc loss compromised plasma cell differentiation for MZ B cells, and reciprocally induced ectopic mTORC1 signaling in follicular B cells enabled division-independent differentiation and plasma cell-affiliated gene expression. We conclude that ongoing in situ Notch2/mTORC1 signaling in MZ B cells establishes a unique cellular state that enables rapid division-independent plasma cell differentiation.
Brian T. Gaudette, Carly J. Roman, Trini A. Ochoa, Daniela Gómez Atria, Derek D. Jones, Christian W. Siebel, Ivan Maillard, David Allman
JCI This Month is a digest of the research, reviews, and other features published each month.
This collection of reviews focuses on the gut-brain axis, highlighting crosstalk between the gastrointestinal tract and the enteric and central nervous systems. While the enteric nervous system can exert independent control over the gut, multi-directional communication with the central nervous system, as well as intestinal epithelial, stromal, immune, and enteroendocrine cells can result in wide-ranging influences on health and disease. The gut microbiome and its metabolites add further complexity to this intricate interactive network. Reviews in this series take a critical approach to describing the role of gut-brain connections in conditions affecting both gut and brain, with the common goal of illuminating the importance of the central and enteric nervous system interface in disease pathogenesis and identifying nodes that offer therapeutic potential.